Glucose Monitoring Device Tested in Heart Failure Patients With Diabetes
Tests a continuous glucose monitor in adults with heart failure and type 2 diabetes.
Plain-language title generated from the registry record
Registry title: CGM Use in Heart Failure
Key facts
- Where
- Atlanta, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT07045298, who can take part
Where in United States
- Grady Health SystemAtlanta, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Emory University
- Trial code
- NCT07045298
- Record updated
- 22 July 2026
- Original description
Heart failure (HF) is a major cause of hospital admissions in the US, with over 6 million hospital days annually.Read full original descriptionShow less
Real-Time Continuous Glucose Monitoring for the Management of Patients With Type 2 Diabetes and Acutely Decompensated Heart Failure
Heart failure (HF) is a major cause of hospital admissions in the US, with over 6 million hospital days annually.
More than 40% of hospitalized patients with HF have diabetes mellitus (DM), which increases the risk of recurrent hospitalizations for HF with reduced and preserved ejection fraction by more than two-fold. Current methods for assessing glycemic control do not consider fluctuations in blood glucose levels, known as glycemic variability. High glycemic variability is a poor prognostic marker for HF re-hospitalizations. Given the significant prevalence and impact of DM in individuals with HF, it is crucial to examine whether improving glycemic control and avoiding hypoglycemia could lead to a decrease in HF readmissions. Real-time continuous glucose monitoring (rt-CGM), which provides glucose measurements as frequently as every 5 minutes, has improved glycemic control in insulin-treated adults with DM compared to the standard of care, capillary point-of-care blood glucose testing (POC). Researchers will monitor participants during their hospital stay and 3 months after discharge.
Inclusion: Adults 18 to 90 years admitted with a diagnosis of acute decompensated heart failure (ADHF), New York Heart Association (NYHA) class II, III, or IV symptoms (Aim 1) and discharged with a clinical diagnosis of ADHF (Aim 2); Patients with diabetes treated with diet alone or oral antidiabetic agents, Glucagon-like peptide-1 receptor agonists (GLP1-RAs), or insulin after discharge.
Exclusion: History of cardiac surgery (within 90 days before enrollment) or planned cardiac interventions within the following 6 months; Patients with a history of type 1 diabetes; Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study; History of a heart transplant or listed for a heart transplant; Age < 18 or > 90 years; Patients on ventricular assist devices; Female participants who are pregnant or breastfeeding at the time of enrollment into the study; Hospice care or expected life expectancy of less than 6 months; Patients who are expected to require Magnetic Resonance Imaging (MRI) procedures during hospitalization or after discharge.